Vaccine Design and Testing – Products

The Center for Emerging Viral Threats (CEVT) in Louisiana, USA, is using INTEGRA Biosciences’ liquid handling solutions for COVID-19 testing and viral genomics studies.

Meissa Vaccines announced it has entered into a manufacturing agreement with Exothera S.A. delivering customized process development and GMP manufacturing services for vaccines, viral vectors and nucleic acids.

New Kit Enables Automation of DNA Cloning on the BioXp® System Beginning from Linear DNA, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Molecular Biology Workstation.

Lipid nanoparticles (LNPs) have emerged as effective delivery vehicles for mRNA vaccines and nucleic acid-based drugs. Hence, the analysis of their composition, stability, and biological interactions is essential in drug development and delivery.

Icosagen Group has announced that it has acquired the LSA® platform from Carterra®.

Voltron Therapeutics, Inc. has signed a new Sponsored Research Agreement with the Vaccine and Immunotherapy Center at Massachusetts General Hospital, Harvard Medical School to initiate a pre-clinical immuno-oncology trial targeting prostate stem cell antigen in prostate, renal cell and urothelial cancers, adding important potential indications to its growing pipeline.

FUJIFILM Irvine Scientific, Inc. has announced the launch of its BalanCD HEK293 Viral Feed.

The Native Antigen Company has announced the commercial release of its Sudan Ebolavirus Boniface 1976 Glycoprotein (SEBOV GP).

AMSBIO has added a new range of Vesicular Stomatitis Virus to its suite of virus-based tools for cell engineering and the study of viral infection.

The Dynabeads™ Streptavidin for in vitro transcription and Dynabeads Carboxylic Acid for RNA purification solutions support scalable GMP-grade synthesis and purification of mRNA for vaccine development and manufacturing.